

# Generation of animal models (mouse or rat) of rare diseases at PHENOMIN-ICS

Marie-Christine Birling, Philippe André, Marie Wattenhofer-Donze, Sylvie Jacquot, Guillaume Pavlovic, Tania Sorg et Yann Hérault

Institut Clinique de la Souris-ICS-MCI, PHENOMIN, CNRS UMR7104, INSERM U964, Université de Strasbourg, 1 rue Laurent Fries BP 10142 Parc d'Innovation 67404 Illkirch, France; \* IGBMC, CNRS UMR7104, INSERM U964, Université de Strasbourg, 1 rue Laurent Fries BP 10142 Parc d'Innovation 67404 Illkirch, France;

Animal models to study human disease have experienced a boom in recent decades. These remain essential models for validating or not the safety part of medicines for their Marketing Authorization. At PHENOMIN-ICS, we can generate the model of choice for your research and assist you with the phenotypic validation of your line.

## Genetic Engineering and Genome Editing

Expert advice

Strategy discussed with the collaborator in order to propose the best possible approach

"À la carte" projects / new tools





Technical and scientific expertise- Highly competent teams

Validation of ES cell clones by long PCR and Southern blot (IMPC and internal clones)

> 1,500 targeted mutagenesis projects using ES cells

>200 CRISPR projects

> 300 transgenesis projects by random insertion





## Types of models

- Constitutive Knock-out (loss of function)
- Conditional knockout
- Knock-In (including Point Mutation)
- Humanization
- Conditional mutation
- Targeted transgenesis (Rosa26)
- Duplication, deletion, region
- Inversion Flex2 type models

## Some examples of mouse models of human diseases obtained at the Institut Clinique de la Souris

- **Malformations pathogéniques congénitales**  
TUBG1: modèle de mutation ponctuelle transformable en KO (Ivanova et al., 2019 Nat Comm); KIF2A: modèle Flex2- mutation conditionnelle (Gilet et al., 2020, HMG; Fig.1)
- **Désordre neuro-développemental**  
ARX: duplication d'une expansion de polyalanine (c.428\_451dup24) (Dubos et al., 2018 HMG, Fig.2)  
CDX2: Surexpression conditionnelle (Grall et al., 2019; Cell Death and Disease. Fig.3)
- **Angiopathie héréditaire avec néphropathie, anévrismes et crampes musculaires (AHNAC)**  
Col4a1<sup>G498V</sup> mutants (Chen et al., 2016, J Am Soc Nephrol; Guiraud et al., 2017, Am J Path)
- **Syndrôme de Bardet-Biedl**  
BBS12: souris perte de fonction (Marion et al., 2012, Cell Metab)
- **Sclérose latérale amyotrophique**  
FUS: delta NLS inductible (Scekic-Zahirovic et al., 2016, EMBO J Fig.4); Scekic-Zahirovic et al., 2017, Acta Neuropath.; Piccarelli et al., 2019, Nat Neurosci)
- **Syndrôme de Costello**
- **Syndrôme LEOPARD**
- PTPN11: mutation ponctuelle T468S (Tanjan et al., 2014, PNAS)
- **Modèles de 'Copy Number Variations'**  
Modèles de Trisomie 21 (Birling et al., 2017, Sci Rep; Fig.5), 17q21.31Bis; 17q21.31-Koolen-deVries (Arbogast et al., 2017, PLOS genetics); 16p11.2 (Arbogast et al., 2016, PLOS genetics)



## To summarize

We routinely modify the genome of mice or rats to generate relevant models that best reproduce the different aspects of the human disease of interest. Thanks to CRISPR technology, it is now possible to quickly generate almost any type of pattern or mutation.

Contact: [birlingm@igbmc.fr](mailto:birlingm@igbmc.fr)

